S1pr2 antagonists and uses therefor
AssigneeDalhousie University
InventorsChristopher McMaster, Gordon Simms
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are compounds which contain bioisosteric replacements of the urea group of JTE-013 and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.
Claims74
A method for treating ocular diseases that are caused by a primary defect in retinal vascularization followed by secondary aberrant neovascularization that can result in retina detachment, the method comprising the administration of a pharmaceutically effective amount of a compound of formula IX, or any pharmaceutically-acceptable salt thereof:
- wherein
- R1 is C1-C12 alkyl;
- R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
- R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
- each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
- n is 0, 1, 2, 3 or 4;
- X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
- Y1 and Y2 are each independently selected from NRa, CH2, and O;
- and
- Z is any geometric isomer of a group selected from one of the following:
A compound for inhibiting SIPR2 receptors to treat an eye condition comprising the following formula IX, or any pharmaceutically-acceptable salt thereof:
- wherein
- R1 is C1-C12 alkyl;
- R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
- R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
- each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
- n is 0, 1, 2, 3 or 4;
- X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
- Y1 and Y2 are each independently selected from NRa, CH2, and O;
- and
- Z is any geometric isomer of a group selected from one of the following:
A method for treating ocular diseases that are caused by a primary defect in retinal vascularization followed by secondary aberrant neovascularization that can result in retina detachment comprising the administration of a pharmaceutically effective amount of a compound selected from the following, or any pharmaceutically-acceptable salt thereof:
A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of a compound of formula IV, or any pharmaceutically-acceptable salt thereof:
- wherein
- Ar is aromatic heterocycle;
- W is NRa—, O, or —CH2—, wherein Ra is hydrogen or C1-C3 alkyl;
- Z is —C(═O)—, —C(═S)—, O, —CH2—, ═N—, or ═CH—;
- Y is —NRa—, —C(═O)—, —N═, —CH═, ═N—, or ═CH—;
- and
- X is —NRa—, —N═, —CH═, or —CH2—;
- R1 is C1-C12 alkyl;
- R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4alkylamino, C3-C7cycloalkyl, or C3-C7cycloalkyloxy;
- R3 and R4 can be positioned at h, i, or j, but not simultaneously at the same position;
- and
- X2 is N or —CRb— wherein Rb is hydrogen, halogen, C1-C6 alkyl, C1-C4alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4alkylamino, C3-C7cycloalkyl, or C3-C7cycloalkyloxy.
A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of at least one compound of formula I to formula X, or any pharmaceutically-acceptable salt thereof.
A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of at least one compound of PubChem ID 3382778, PubChem ID 44317142, PubChem ID 54736865, PubChem ID 3866342, PubChem ID 46891770, PubChem ID 51624406, PubChem ID 9578291, PubChem ID 9864156, PubChem ID 365015, PubChem ID 28094480, PubChem ID 40592676, PubChem ID 10883396, PubChem ID 342302, PubChem ID 59623845, PubChem ID 54734912, PubChem ID 18390590, PubChem ID 56923928, PubChem ID 51508548, PubChem ID 28960354, PubChem ID 51624683, or PubChem ID 27993, or any pharmaceutically-acceptable salt thereof.
A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of at least one compound of formula I to formula X, or any pharmaceutically-acceptable salt thereof.
A compound for inhibiting SIPR2 receptors to treat an eye condition comprising the following formula IX, or any pharmaceutically-acceptable salt thereof:
- wherein
- R1 is C1-C12 alkyl;
- R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
- R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
- each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
- n is 0, 1, 2, 3 or 4;
- X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
- Y1 and Y2 are each independently selected from NRa, CH2, and O;
- and
- Z is any geometric isomer of a group selected from one of the following:
A compound of general formula (IX),
- wherein
- R1 is C1-C12 alkyl;
- R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
- R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
- each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
- n is 0, 1, 2, 3 or 4;
- X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
- Y1 and Y2 are each independently selected from NRa, CH2, and O;
- and
- Z is any geometric isomer of a group selected from one of the following:
- or any pharmaceutically acceptable salt thereof.
A compound of general formula (X),
- wherein,
- R1 is C1-C12 alkyl;
- R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
- R3 and R4 can be positioned at h, i, or j, but not simultaneously at the same position;
- each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
- n is 0, 1, 2, 3 or 4;
- X and Y are each independently selected from NRa, O, and CH2, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
- and Z is any geometric isomer of a group selected from one of the following:
- or any pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.